ESMO 2023: Agenus' Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma Subtypes | Business

LEXINGTON, Mass.--(BUSINESS WIRE)--Oct 21, 2023--

Related Keywords

Colorado ,United States ,Massachusetts ,Breelyn Wilky ,Breelyna Wilky ,Agenus Inc ,Nasdaq ,Exchange Commission ,Clinical Research ,University Of Colorado Cancer Center ,European Society For Medical Oncology ,University Of Colorado ,European Society ,Medical Oncology ,Steveno Day ,Chief Medical ,Sarcoma Medical Oncology ,Deputy Associate Director ,Colorado Cancer ,Risk Factors ,Quarterly Report ,Annual Report ,Business Wire ,Business ,